We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced a collaboration with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Both companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.
Per the terms, Tentarix will get upfront payments and an equity investment from Gilead totaling $66 million across the three collaborations. Gilead will have the option to acquire up to three select Tentarix subsidiaries containing the programs developed under the collaborations for $80 million per subsidiary.
Gilead expects Tentarix to complement its ongoing efforts, build upon its growing strength in protein therapeutics and provide access to next-generation, multi-specific biologics.
Gilead expects this transaction to reduce its bottom line in 2023 (both on a GAAP and a non-GAAP basis) by approximately 3-4 cents.
Shares of Gilead have lost 7.3% in the year so far compared with the industry’s decline of 12.6%.
Image Source: Zacks Investment Research
GILD is looking to diversify in the lucrative oncology space as competition is stiffening in its HIV business, which has been the growth engine.
The oncology business put up a stellar performance in the first half of 2023, fueling its top line. The Cell Therapy franchise, comprising Yescarta and Tecartus, continues to witness a steady increase in sales, primarily due to higher demand for Yescarta in relapsed or refractory (r/r) large B-cell lymphoma and Tecartus in adult R/R B-cell precursor acute lymphoblastic leukemia and mantle cell lymphoma in the United States and Europe.
The uptake of the breast cancer drug Trodelvy has been robust due to increased adoption in pre-treated HR+/HER2- metastatic breast cancer in the United States.
Gilead is making efforts to strengthen its pipeline in this space through strategic collaborations and acquisitions and is not investing in developing a candidate from scratch in the oncology space.
In May 2023, Gilead acquired the privately held biotech company XinThera. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets in oncology and inflammation.
Earlier, it entered into a strategic collaboration with Arcellx, Inc. (ACLX - Free Report) to co-develop and co-commercialize CART-ddBMCA, a late-stage clinical asset in development for the treatment of multiple myeloma.
However, Arcellx announced that the FDA placed a clinical hold on its iMMagine-1 program, designed to evaluate the lead program, CART-ddBCMA, for treating adult patients with relapsed or refractory multiple myeloma. The hold was placed on Jun 16 after a patient died.
Arcellx believes limitations on bridging therapy are a contributing factor and is working with the FDA to amend the protocol to expand options for patients that are consistent with current clinical practice.
The loss per share estimate for SPRO for 2023 has narrowed by 54 cents to 51 cents in the past 30 days. Spero’s earnings beat estimates in all of the trailing four quarters, the average surprise being 72.43%.
The loss per share estimate for DVAX has narrowed by 5 cents to 27 cents for 2023 in the past 30 days. Dynavax has risen 33.8% in the year-to-date period. DVAX’s earnings beat estimates in two of the trailing four quarters and missed in the remaining two, the average surprise being 25.78%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
Gilead Sciences, Inc. (GILD - Free Report) announced a collaboration with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Both companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.
Per the terms, Tentarix will get upfront payments and an equity investment from Gilead totaling $66 million across the three collaborations. Gilead will have the option to acquire up to three select Tentarix subsidiaries containing the programs developed under the collaborations for $80 million per subsidiary.
Gilead expects Tentarix to complement its ongoing efforts, build upon its growing strength in protein therapeutics and provide access to next-generation, multi-specific biologics.
Gilead expects this transaction to reduce its bottom line in 2023 (both on a GAAP and a non-GAAP basis) by approximately 3-4 cents.
Shares of Gilead have lost 7.3% in the year so far compared with the industry’s decline of 12.6%.
Image Source: Zacks Investment Research
GILD is looking to diversify in the lucrative oncology space as competition is stiffening in its HIV business, which has been the growth engine.
The oncology business put up a stellar performance in the first half of 2023, fueling its top line. The Cell Therapy franchise, comprising Yescarta and Tecartus, continues to witness a steady increase in sales, primarily due to higher demand for Yescarta in relapsed or refractory (r/r) large B-cell lymphoma and Tecartus in adult R/R B-cell precursor acute lymphoblastic leukemia and mantle cell lymphoma in the United States and Europe.
The uptake of the breast cancer drug Trodelvy has been robust due to increased adoption in pre-treated HR+/HER2- metastatic breast cancer in the United States.
Gilead is making efforts to strengthen its pipeline in this space through strategic collaborations and acquisitions and is not investing in developing a candidate from scratch in the oncology space.
In May 2023, Gilead acquired the privately held biotech company XinThera. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets in oncology and inflammation.
Earlier, it entered into a strategic collaboration with Arcellx, Inc. (ACLX - Free Report) to co-develop and co-commercialize CART-ddBMCA, a late-stage clinical asset in development for the treatment of multiple myeloma.
However, Arcellx announced that the FDA placed a clinical hold on its iMMagine-1 program, designed to evaluate the lead program, CART-ddBCMA, for treating adult patients with relapsed or refractory multiple myeloma. The hold was placed on Jun 16 after a patient died.
Arcellx believes limitations on bridging therapy are a contributing factor and is working with the FDA to amend the protocol to expand options for patients that are consistent with current clinical practice.
Zacks Rank & Stocks to Consider
Gilead currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the overall healthcare sector are Spero Therapeutics (SPRO - Free Report) and Dynavax Technologies (DVAX - Free Report) . While SPRO sports a Zacks Rank #1 (Strong Buy), DVAX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The loss per share estimate for SPRO for 2023 has narrowed by 54 cents to 51 cents in the past 30 days. Spero’s earnings beat estimates in all of the trailing four quarters, the average surprise being 72.43%.
The loss per share estimate for DVAX has narrowed by 5 cents to 27 cents for 2023 in the past 30 days. Dynavax has risen 33.8% in the year-to-date period. DVAX’s earnings beat estimates in two of the trailing four quarters and missed in the remaining two, the average surprise being 25.78%.